Kuzmanić Dusko, Laganović Mario, Dika Zivka, Kos Jelena, Pećin Ivan
Zavod za nefrologiju i arterijsku hipertenziju Klinike za unutrasnje bolesti KBC Zagreb, Kispatićeva 12, 10 000 Zagreb.
Lijec Vjesn. 2006 Nov-Dec;128(11-12):336-41.
Arterial hypertension is frequently associated with type 2 diabetes mellitus, and both of these diseases are the major risk factors for cardiovascular complications. During the past few years, a number of large randomized clinical trials examined the frequency of new onset diabetes mellitus during administration of antihypertensive drugs. Application of ACE inhibitors or angiotensin receptor blockers reduces the risk for the onset of diabetes mellitus by 20-27%, and calcium channel blockers by 16%. Despite some uncertainties, novel studies have demonstrated an increased risk for cardiovascular complications related to new onset diabetes mellitus. The duration of patient monitoring is also an important factor, as the onset of diabetes-related complications is closely associated with the duration of this disease. Considering all above, the aim of preventing the onset of diabetes is to recognize patients with an increased risk. The risk factors include basal glycemia, positive family history for diabetes mellitus, obesity, metabolic syndrome, and some ethnic groups (South Asia, the Caribbeans). Therefore, increased-risk patients should be subjected to therapy with ACE inhibitor, angiotensin receptor blocker, or calcium channel blocker as the first drug of choice. For these patients, application of thiazides and beta blockers or the combination of these two drugs is not advantageous. However, such a view poses a dilemma whether thiazide diuretics should be the first choice in the treatment of hypertension.
动脉高血压常与2型糖尿病相关,这两种疾病都是心血管并发症的主要危险因素。在过去几年中,一些大型随机临床试验研究了服用抗高血压药物期间新发糖尿病的发生率。应用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂可使糖尿病发病风险降低20%-27%,钙通道阻滞剂可降低16%。尽管存在一些不确定性,但新的研究表明,新发糖尿病相关的心血管并发症风险增加。患者监测的时长也是一个重要因素,因为糖尿病相关并发症的发生与该病的病程密切相关。综合以上因素,预防糖尿病发病的目的是识别风险增加的患者。风险因素包括基础血糖、糖尿病家族史阳性、肥胖、代谢综合征以及一些种族群体(南亚、加勒比地区)。因此,风险增加的患者应以血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂或钙通道阻滞剂作为首选药物进行治疗。对于这些患者,应用噻嗪类药物和β受体阻滞剂或这两种药物的联合使用并无益处。然而,这样的观点引发了一个两难问题,即噻嗪类利尿剂是否应作为高血压治疗的首选药物。